http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
TROPHIT1—a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients
Köhler, B. C.DKFZ* ; Haag, G. M. (First author)DKFZ* ; Le Cornet, L.DKFZ* ; Hoffmeister-Wittmann, P.DKFZ* ; Schmidt, M.DKFZ* ; Manjunath, A. ; Vaquero-Siguero, N.DKFZ* ; Jenzer, M. ; Gimmel, M. ; Stahler, A. ; Stein, A. ; Reichert, M. ; Kasper, S. ; Bitzer, M. ; Jäger, D.DKFZ* ; Springfeld, C. ; Weber, T. F.DKFZ* ; Fröhling, S.DKFZ* ; Steindorf, K.DKFZ* ; Trumpp, A.DKFZ* ; Schlenk, R. F. ; Jackstadt, R.-F. (Last author)DKFZ*
2025
Elsevier B.V.
[Amsterdam]
Note: DKFZ-ZMBH Alliance / #EA:D120#LA:A013#
Contributing Institute(s):
- DKTK HD zentral (HD01)
- Angewandte Tumor-Immunität (D120)
- Krebsepidemiologie (C180)
- Bewegung, Krebsprävention und Survivorship (C110)
- Translationale Medizinische Onkologie (B340)
- A010 Stammzellen und Krebs (A010)
- NWG Tumorprogression und Metastasierung (A013)
Research Program(s):
- 311 - Zellbiologie und Tumorbiologie (POF4-311) (POF4-311)
Appears in the scientific report
2025
Database coverage:
; Article Processing Charges ; DOAJ Seal ; Fees